Key facts
- It has raised $7.2M across 1 recorded rounds; the latest was Accelerator/Incubator in Jan 2023.
- Notable investors include SOSV, Springboard Enterprises, United States Department of War, IndieBio, New York Ventures — 17 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Cayuga Biotech
Funding rounds
1 roundsAbout Cayuga Biotech
Developer of a clinical-stage biopharmaceutical company designed to address life-threatening hemorrhage by harnessing the body's innate ability to stop bleeding. The company offers a pipeline of therapies, including a polyP-SNP complex for acute major hemorrhage, programs for inherited bleeding disorders, and early-stage healing initiatives, enabling patients with serious bleeding conditions to achieve improved recovery and survival outcomes.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2015
- Employees
- 2
- Website
- cayugabiotech.com/
- Ownership
- Privately Held (backing)
Cayuga Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cayuga Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cayuga Biotech in its N-PORT filings yet. We sweep new filings monthly.